Like Novartis before it, AstraZeneca benefits big time from Ranbaxy issues – FiercePharma

“Ranbaxy Laboratories in June finally managed to finesse its regulatory problems enough to get a generic of Novartis’ ($NVS) Diovan to market, boosting its own fortunes while depriving the Swiss drugmaker of the extra revenues it enjoyed for nearly two years. Next up is a generic of AstraZeneca ($AZN) blockbuster Nexium. The question remains when.”

From – FiercePharma